Affimed N.V. is a clinical-stage biopharmaceutical company that specializes in developing targeted immunotherapies for patients with cancer and other serious diseases. The company is headquartered in Heidelberg, Germany and was founded in 2000.
Affimed's core technology is its proprietary Redirected Optimized Cell Killing (ROCK®) platform, which enables the creation of highly potent, bispecific antibodies that can target cancer cells with high specificity and kill them. The ROCK platform has the potential to improve the effectiveness of cancer treatments and reduce side effects compared to traditional chemotherapy.
In addition to its ROCK platform, Affimed is developing a range of other products and therapies that target cancer and other diseases, including a variety of immuno-oncology candidates. The company's products and therapies are designed to improve patient outcomes and reduce the burden of cancer and other serious diseases.
Affimed is committed to innovation and is dedicated to developing new technologies and solutions to improve the diagnosis and treatment of cancer and other diseases. The company's management team has extensive experience in the biopharmaceutical industry and is focused on delivering high-quality products and services to its customers.
In addition to its focus on innovation and product development, Affimed is also committed to social responsibility and sustainability. The company has implemented a number of programs to reduce its environmental impact and support its local communities.
Affimed has a strong track record of financial performance and growth. The company has received numerous awards and recognitions for its innovative technology and management, and has been recognized as a leading biopharmaceutical company in Germany.
Affimed N.V. is a clinical-stage biopharmaceutical company that specializes in developing targeted immunotherapies for patients with cancer and other serious diseases. With a focus on innovation, social responsibility, and sustainability, Affimed is well-positioned to continue driving growth and delivering value to its customers and stakeholders in the years ahead.